Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 14

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  glutamine
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
Glutamine is involved in many metabolic pathways such as generation of amino acids, nucleotides and glutathione. Glutamine also serves in pH homeostasis, urea formation, immune response and wound healing. In addition, glutamine is considered to be the primary precursor of the fast neurotransmitters glutamate and GABA in the central nervous system (CNS). The prevailing hypothesis of a glutamate/GABA-glutamine cycle suggests that a large amount of released glutamate and GABA are translocated into perisynaptic astroglial cells, converted into glutamine, and subsequently shuttled back to neurons for regeneration of the neurotransmitters. This mechanistic view is supported by differential localization of glutamate and GABA transporters on perisynaptic glial processes, and demonstration of the key glutamine metabolizing enzymes glutamine synthetase (GS) and phosphate-activated glutaminase (PAG) in glial cells and nerve terminals, respectively. However, the molecular mechanisms involved in glutamine extrusion from glial cells and its transport into neurons have until recently eluded characterization. We have molecularly identified a family of amino acid transporters (Slc38) with isoform specific characteristics. We show that the system A transporters (SATs) mediate neuronal transport of glutamine. SAT1 is enriched in GAD67 expressing GABAergic neurons suggesting a role in GABA formation. SAT2 expression is pronounced in the somatodendritic domains of glutamatergic neurons where it sustains formation of glutamate and is intrinsic for retrograde signaling. Activity of the homologous system N transporter SN1 – expressed exclusively on astroglial cell membranes – is dynamically regulated by intracellular protein kinases and may fine-tune extracellular levels of glutamine accessible for neuronal uptake. SN2 – also expressed in the astroglial cells, but with differential subcellular localization – mediates glutamine release for neurotransmitter synthesis and glycine release to regulate NMDA receptors. Finally, we have shown that these transporters also contribute to pH restoration during chronic metabolic acidosis and regulation of insulin secretion. Recently, I have also contributed to the investigation of a child with congenital glutamine synthetase deficiency, who developed generalized hypotonia and hyperreflexia and treatment-resistant seizures postpartum and had very low serum and cerebrospinal fluid concentrations of glutamine and glutamate (Häberle et al. 2012). Glutamine supplementation restored serum levels of glutamine and glutamate, while corresponding values in the CNS approached normal. Ammonia toxicity was also prevented. The frequency of seizures abated and EEG showed significant improvement. Altogether, our data show the importance of glutamine and glutamine transporters in normal physiology and pathophysiology and bolster existence of a glutamate/GABA-glutamine cycle.
The aim of this study was to asses the effect of glutamine-supplemented total parenteral feeding on clinical and nutritional states in severe inflammatory bowel diseases (IBD). Twenty seven patients with severe IBD were qualified to total parenteral feeding with or without glutamine. The clinical, metabolic and nutritional improvements have been analyzed after 14-day treatment. Though, we were able to notice some improvements in hemoglobin and transferrin concentrations as well as nitrogen balance, it still cannot be strongly concluded that these effects were due to glutamine supplementation. There were any beneficial effects of glutamine on immunological, biochemical nor anthropometric parameters of nutritional status.
Pisum arvense plants were subjected to 5 days of nitrogen deprivation. Then, in the conditions that increased or decreased the root glutamine and asparagine pools, the uptake rates of 0.5 mM NH₄⁺ and 0.5 mM K⁺ were examined. The plants supplied with 1 mM glutamine or asparagine took up ammonium and potassium at rates lower than those for the control plants. The uptake rates of NH₄⁺ and K⁺ were not affected by 1 mM glutamate. When the plants were pre-treated with 100 µM methionine sulphoximine, an inhibitor of glutamine synthesis, the efflux of NH₄⁺ from roots to ambient solution was enhanced. On the other hand, exposure of plants to methionine sulphoximine led to an increase in potassium uptake rate. The addition of asparagine, glutamine or glutamate into the incubation medium caused a decline in the rate of NH₄⁺ uptake by plasma membrane vesicles isolated from roots of Pisum arvense, whereas on addition of methionine sulphoximine increased ammonium uptake. The results indicate that both NH₄⁺ and K⁺ uptake appear to be similarly affected by glutamine and asparagine status in root cells.
The nutritional and physiological roles of amino acid (AA)s have been investigated for individual organs. In the current study, we focused on the dynamics of glutamate and transport systems in the pancreas. We employed original procedures to obtain rat pancreatic juice (PJ) subjected to intravenous administration of alanyl-glutamine (AG) for AA analysis. The pancreatic expressions of the transporters were evaluated by immunohistochemistry. We found that glutamate was secreted into the PJ in the basal state. The intravenous administration of AG increased the concentration and total amount of glutamate excreted into the PJ. In terms of the transport systems, L-type AA transporter (LAT1) was identified exclusively in the islet cells. Glutamate transporter 1 (GLT1), glutamate-aspartate transporter (GLAST), vesicular glutamate transporter 1 (VGUT1) and cystine/glutamic acid transporter (xCT) were found in the islet cells. xCT was identified in the duct cells as well, but was not accompanied by the expression of 4F2 heavy chain (4F2hc) staining in the islets and the acinar cells, similar to neutral AA transporter (ASCT2) or b0,+-type AA transporter 1(BAT1). Excitatory AA transporter (EAAC) was identified only in the acinar cells. Glutamate was exclusively found in the acinar cells. We revealed the novel dynamics of glutamate in the rat PJ. The glutamate secretion into the PJ was augmented by plasma glutamine, indicating the de novo metabolisms of glutamate, together with the local expression of the related transporters.
Despite its widespread use, the mechanisms of valproic acid (VPA) action are not fully understood. In the current study, we have examined the peripheral and central effects of VPA administration on the metabolic pathway of tryptophan (TRP): concentration of its centrally active metabolites, kynurenine (KYN) and kynurenic acid (KYNA). Moreover, the role of a displacement of TRP from serum albumin binding sites, and changes in the peripheral and central concentration of amino acid including glutamate (GLU), GABA, alanine (ALA), glutamine (GLTM), glycine (GLY), aspartate (ASP), were also studied. We found that VPA administration produced a progressive and strong increase in the central concentration of KYNA, KYN and TRP. Simultaneously, TRP concentration in plasma declined while the peripheral increase of KYNA in plasma was weaker and occurred earlier than in the hippocampus. We also observed that administration of ibuprofen to rats, a prototypic drug used to study drug binding to serum albumin, strongly increased the amount of a free serum and hippocampal TRP concentration, to a degree similar to the effect of VPA. Moreover, we found that the most pronounced changes in the concentration of amino acids caused by administration of VPA include an increase of GLU and a decrease of ALA in the plasma as well as a decrease of ASP and an increase of GABA in the brain. The factor analysis revealed that the changes in the concentrations of TRP, determined both in the plasma and in the hippocampus grouped strongly with the changes in the plasma concentrations of GLU and the central concentration of ASP. Our results showed that administration of VPA strongly modifies the activity of the kynurenine pathway with significant changes in TRP, KYN and KYNA levels in the CNS. The reason for this may be a strong VPA-induced displacement of TRP from its binding sites to plasma albumin. It appears also that the changes in TRP evoked by VPA administration due to competition for transport into the brain, may result in a shift in the central and peripheral balance between branched-chain (BCAA) and aromatic amino acids (AAA). This may lead to a decrease in BCAA transport to the brain, leading to a deficit of BCAAs as a donor of amino groups to the process of GLU resynthesis from pyruvate. Changes in the BCAA/ AAA ratio, arising as a consequence of changes in the TRP level, could explain an observed increase in the plasma concentrations of GLU and a decrease in the ASP concentrations in the brain that occurred after administration of VPA. In sum, given the neuroprotective role of KYNA, the current study suggests that stimulation of the kynurenine pathway may also apply to the central and peripheral concentration of amino acids. The modification of the activity of the kynurenine pathway may at least in part contribute to the related antiepileptic and neuroprotective mechanisms of VPA action.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.